Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free PRME Stock Alerts

Prime Medicine (PRME) Financials

Prime Medicine logo
$3.87 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$3.93 +0.06 (+1.50%)
As of 07/2/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Prime Medicine

Annual Income Statements for Prime Medicine

This table shows Prime Medicine's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -184 -142 -198 -196 -201
Consolidated Net Income / (Loss)		 -3.41 -165 -122 -198 -196 -201
Net Income / (Loss) Continuing Operations		 -3.41 -165 -122 -198 -196 -201
Total Pre-Tax Income 		-1.54 -166 -123 -198 -196 -201
Total Operating Income		 -0.93 -84 -117 -205 -202 -208
Total Gross Profit		 5.21 0.00 0.00 0.00 2.98 4.63
Total Revenue		 5.21 0.00 0.00 0.00 2.98 4.63
Operating Revenue		 5.21 0.00 - 0.00 2.98 4.63
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 6.14 84 117 205 205 213
Selling, General & Admin Expense		 3.16 14 30 43 50 52
Research & Development Expense		 2.98 71 87 148 155 161
Total Other Income / (Expense), net		 -0.61 -81 -6.23 6.38 6.59 7.21
Interest & Investment Income		 - - - 2.81 3.52 4.15
Other Income / (Expense), net		 -0.61 -81 -6.23 3.57 3.06 3.06
Basic Earnings per Share		 ($1.91) ($14.19) ($4.19) ($2.18) ($1.65) ($1.35)
Weighted Average Basic Shares Outstanding		 2.64M 12.97M 33.89M 90.97M 118.60M 148.76M
Diluted Earnings per Share		 ($1.91) ($14.19) ($4.19) ($2.18) ($1.65) ($1.35)
Weighted Average Diluted Shares Outstanding		 2.64M 12.97M 33.89M 90.97M 118.60M 148.76M
Weighted Average Basic & Diluted Shares Outstanding		 - - 97.25M 119.94M 131.16M 180.55M

Quarterly Income Statements for Prime Medicine

This table shows Prime Medicine's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Consolidated Net Income / (Loss)		 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Net Income / (Loss) Continuing Operations		 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Total Pre-Tax Income 		-51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Total Operating Income		 -51 -68 -48 -56 -54 -44 -52 -53 -54 -49 -51
Total Gross Profit		 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84 0.86
Total Revenue		 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84 0.86
Operating Revenue		 0.00 - 0.59 0.00 0.21 2.18 1.45 1.12 1.23 0.84 0.86
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 51 68 49 56 54 46 54 54 55 49 52
Selling, General & Admin Expense		 10 13 11 13 14 12 13 13 11 15 17
Research & Development Expense		 41 41 38 43 40 34 41 41 44 35 34
Total Other Income / (Expense), net		 0.64 2.40 2.71 0.21 1.71 1.95 0.50 0.79 3.39 2.53 1.53
Interest & Investment Income		 0.41 - 0.68 0.61 0.70 - 1.18 0.74 1.14 1.08 1.02
Other Income / (Expense), net		 0.23 0.63 2.04 -0.40 1.02 -0.27 -0.68 0.04 2.25 1.45 0.51
Basic Earnings per Share		 ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22) ($0.28)
Weighted Average Basic Shares Outstanding		 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M 177.10M
Diluted Earnings per Share		 ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22) ($0.28)
Weighted Average Diluted Shares Outstanding		 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M 177.10M
Weighted Average Basic & Diluted Shares Outstanding		 97.32M 119.94M 120.03M 120.03M 131.16M 131.16M 131.29M 134.57M 180.51M 180.55M 180.62M

Annual Cash Flow Statements for Prime Medicine

This table details how cash moves in and out of Prime Medicine's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 28 162 2.57 -146 141 -120
Net Cash From Operating Activities		 -5.54 -34 -132 -165 -123 -163
Net Cash From Continuing Operating Activities		 -5.54 -34 -132 -165 -123 -163
Net Income / (Loss) Continuing Operations		 -3.41 -165 -122 -198 -196 -201
Consolidated Net Income / (Loss)		 -3.41 -165 -122 -198 -196 -201
Depreciation Expense		 0.04 0.57 2.22 4.65 6.13 7.32
Amortization Expense		 0.00 0.72 -0.25 -3.41 -3.09 -1.94
Non-Cash Adjustments To Reconcile Net Income		 -4.21 99 24 43 25 39
Changes in Operating Assets and Liabilities, net		 2.03 31 -36 -11 45 -5.34
Net Cash From Investing Activities		 -1.06 -74 -47 19 68 -109
Net Cash From Continuing Investing Activities		 -1.06 -74 -47 19 68 -109
Purchase of Property, Plant & Equipment		 -0.64 -4.15 -16 -8.72 -7.29 -4.53
Purchase of Investments		 0.00 -82 -123 -105 -129 -205
Sale and/or Maturity of Investments		 0.00 13 93 133 204 101
Other Investing Activities, net		 -0.42 -0.50 -0.67 -0.17 1.00 0.00
Net Cash From Financing Activities		 35 269 181 0.66 196 152
Net Cash From Continuing Financing Activities		 35 269 181 0.66 196 152
Issuance of Debt		 - - - 0.00 132 138
Issuance of Common Equity		 0.00 0.00 185 0.00 58 0.34
Other Financing Activities, net		 0.00 0.00 0.22 0.66 6.10 13

Quarterly Cash Flow Statements for Prime Medicine

This table details how cash moves in and out of Prime Medicine's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -77 -2.39 53 -39 63 64 -91 -38 18 -8.36 1.07
Net Cash From Operating Activities		 -39 -44 -68 -45 -26 16 -49 -41 -35 -37 -43
Net Cash From Continuing Operating Activities		 -39 -44 -68 -45 -26 16 -49 -41 -35 -37 -43
Net Income / (Loss) Continuing Operations		 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Consolidated Net Income / (Loss)		 -51 -66 -46 -55 -53 -42 -52 -53 -51 -46 -49
Depreciation Expense		 1.24 1.25 1.32 1.54 1.56 1.72 1.70 1.86 1.88 1.88 1.86
Amortization Expense		 -0.92 -1.09 -0.68 -1.40 -0.87 -0.15 -0.16 -0.41 -0.57 -0.79 -0.43
Non-Cash Adjustments To Reconcile Net Income		 8.93 21 -6.11 15 8.84 8.09 9.15 9.18 14 6.58 7.49
Changes in Operating Assets and Liabilities, net		 2.29 0.95 -16 -4.88 17 49 -7.65 0.55 0.61 1.16 -2.50
Net Cash From Investing Activities		 -38 41 -37 6.89 50 48 -48 2.77 -92 28 43
Net Cash From Continuing Investing Activities		 -38 41 -37 6.89 50 48 -48 2.77 -92 28 43
Purchase of Property, Plant & Equipment		 -2.91 -1.84 -2.32 -1.90 -1.28 -1.79 -2.42 -1.57 -0.25 -0.29 -0.21
Purchase of Investments		 -55 -4.41 -107 -29 -10 17 -48 -6.91 -134 -16 -7.28
Sale and/or Maturity of Investments		 20 48 73 38 61 33 3.00 11 42 45 51
Net Cash From Financing Activities		 0.32 0.19 157 0.04 39 0.00 6.00 0.20 145 0.56 0.39
Net Cash From Continuing Financing Activities		 0.32 0.19 157 0.04 39 0.00 6.00 0.20 145 0.56 0.39
Other Financing Activities, net		 0.32 0.19 6.04 0.04 0.03 - 6.00 - 6.37 0.41 0.39

Annual Balance Sheets for Prime Medicine

This table presents Prime Medicine's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 302 360 194 298 343
Total Current Assets		 271 297 143 212 181
Cash & Equivalents		 185 188 42 182 63
Short-Term Investments		 68 106 80 7.97 115
Prepaid Expenses		 0.96 2.45 19 6.78 2.94
Other Current Assets		 16 0.25 2.25 15 0.67
Plant, Property, & Equipment, net		 4.93 19 23 24 21
Total Noncurrent Assets		 26 45 28 61 141
Other Noncurrent Operating Assets		 26 45 28 61 141
Total Liabilities & Shareholders' Equity		 302 360 194 298 343
Total Liabilities		 62 44 61 144 222
Total Current Liabilities		 58 27 56 38 37
Accounts Payable		 1.44 4.33 20 11 8.89
Accrued Expenses		 37 11 28 16 13
Current Deferred Revenue		 - - 0.00 7.09 7.82
Other Current Liabilities		 19 12 9.28 3.61 8.14
Total Noncurrent Liabilities		 4.31 17 4.36 106 184
Noncurrent Deferred Revenue		 - - 0.00 63 58
Other Noncurrent Operating Liabilities		 3.07 17 4.36 43 126
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -156 316 133 153 121
Total Preferred & Common Equity		 -156 316 133 153 121
Total Common Equity		 -156 316 133 153 121
Common Stock		 15 610 624 840 1,009
Retained Earnings		 -171 -293 -491 -687 -888
Accumulated Other Comprehensive Income / (Loss)		 -0.03 -0.38 -0.02 0.00 0.08

Quarterly Balance Sheets for Prime Medicine

This table presents Prime Medicine's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 281 239 311 260 333 328 279 385 295
Total Current Assets		 218 185 218 171 246 164 121 231 138
Cash & Equivalents		 121 44 94 56 118 92 54 71 64
Short-Term Investments		 87 121 117 107 58 52 48 142 71
Prepaid Expenses		 11 19 4.20 4.20 6.01 2.95 3.03 2.49 1.97
Other Current Assets		 - - 2.73 3.74 9.54 17 16 16 0.42
Plant, Property, & Equipment, net		 21 22 24 24 23 25 24 22 19
Total Noncurrent Assets		 42 33 70 65 63 139 134 132 138
Other Noncurrent Operating Assets		 42 33 70 65 63 139 134 132 138
Total Liabilities & Shareholders' Equity		 281 239 311 260 333 328 279 385 295
Total Liabilities		 41 45 68 63 143 221 218 223 218
Total Current Liabilities		 29 39 24 21 38 34 34 35 36
Accounts Payable		 5.49 14 10 4.64 5.43 10 6.38 9.35 12
Accrued Expenses		 9.72 14 7.61 11 19 9.19 12 11 8.10
Current Deferred Revenue		 - - - - 9.28 8.21 8.32 6.95 7.32
Other Current Liabilities		 14 11 6.75 5.22 4.48 6.86 7.26 7.71 8.55
Total Noncurrent Liabilities		 12 5.82 43 42 105 187 184 188 182
Noncurrent Deferred Revenue		 - - - - 63 61 60 60 58
Other Noncurrent Operating Liabilities		 12 5.82 43 42 43 126 124 128 124
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 240 194 244 197 190 107 61 162 77
Total Preferred & Common Equity		 240 194 244 197 190 107 61 162 77
Total Common Equity		 240 194 244 197 190 107 61 162 77
Common Stock		 615 620 781 789 834 846 853 1,004 1,014
Retained Earnings		 -375 -426 -537 -592 -645 -739 -792 -842 -937
Accumulated Other Comprehensive Income / (Loss)		 -0.27 -0.15 -0.10 -0.07 0.02 -0.02 -0.01 0.03 -0.00

Annual Metrics And Ratios for Prime Medicine

This table displays calculated financial ratios and metrics derived from Prime Medicine's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 97,208,342.00 97,324,301.00 - 180,510,658.00
DEI Adjusted Shares Outstanding		 0.00 0.00 97,208,342.00 97,324,301.00 - 180,510,658.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.46 -2.04 - -1.11
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -0.65 -59 -82 -143 -142 -146
Return On Investment Capital (ROIC_SIMPLE)		 - - - -107.73% -92.54% -120.66%
Earnings before Interest and Taxes (EBIT)		 -1.54 -166 -123 -201 -199 -205
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.50 -165 -121 -200 -196 -200
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -118 -132 -93 -126
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.00 -14 22 11 -37 -57
Increase / (Decrease) in Invested Capital		 0.00 -14 36 -11 -49 -20
Book Value per Share		 $0.00 ($12.04) $3.25 $1.37 $1.17 $0.67
Tangible Book Value per Share		 $0.00 ($12.04) $3.25 $1.37 $1.17 $0.67
Total Capital		 0.00 240 316 133 153 121
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -254 -294 -122 -190 -178
Capital Expenditures (CapEx)		 0.64 4.15 16 8.72 7.29 4.53
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -41 -24 -35 -17 -34
Debt-free Net Working Capital (DFNWC)		 0.00 213 270 87 174 144
Net Working Capital (NWC)		 0.00 213 270 87 174 144
Net Nonoperating Expense (NNE)		 2.76 106 40 55 54 55
Net Nonoperating Obligations (NNO)		 0.00 -254 -294 -122 -190 -178
Total Depreciation and Amortization (D&A)		 0.04 1.28 1.97 1.25 3.03 5.38
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($4.19) ($2.18) ($1.65) ($1.35)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 33.89M 90.97M 118.60M 148.76M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($4.19) ($2.18) ($1.65) ($1.35)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 33.89M 90.97M 118.60M 148.76M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 97.25M 119.94M 131.16M 180.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.65 -59 -82 -143 -142 -146
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Prime Medicine

This table displays calculated financial ratios and metrics derived from Prime Medicine's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 97,300,310.00 97,324,301.00 119,939,247.00 120,030,813.00 120,030,813.00 - 131,160,842.00 131,294,454.00 134,573,998.00 180,510,658.00 180,552,179.00
DEI Adjusted Shares Outstanding		 97,300,310.00 97,324,301.00 119,939,247.00 120,030,813.00 120,030,813.00 - 131,160,842.00 131,294,454.00 134,573,998.00 180,510,658.00 180,552,179.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.52 -0.67 -0.38 -0.46 -0.44 - -0.40 -0.40 -0.38 -0.26 -0.27
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 146.02% 0.00% 486.12% - -41.13%
EBITDA Growth		 -77.65% -72.66% -16.61% -31.12% -3.18% 36.18% -12.86% 7.25% 4.02% - 5.47%
EBIT Growth		 -75.80% -70.79% -16.93% -30.43% -3.88% 34.00% -14.62% 4.88% 2.80% - 5.52%
NOPAT Growth		 -62.56% -75.89% -20.75% -23.01% -5.39% 35.01% -8.38% 4.12% 0.48% - 3.32%
Net Income Growth		 -72.77% -67.10% -16.15% -30.53% -3.57% 35.60% -13.39% 4.95% 3.69% - 5.33%
EPS Growth		 65.84% -194.74% 0.00% 2.13% 20.00% 56.94% 9.09% 10.87% 27.27% - 30.00%
Operating Cash Flow Growth		 -30.13% -42.82% -62.91% -11.44% 33.84% 137.03% 27.84% 8.97% -35.22% - 12.58%
Free Cash Flow Firm Growth		 49.64% 0.00% 50.40% 37.34% 19.88% 148.36% 207.10% 192.64% 218.72% - -141.52%
Invested Capital Growth		 -19.51% -48.96% -6.70% 3.81% -51.20% -426.96% -212.98% -221.26% -468.22% - -57.50%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -100.00% 0.00% 944.50% -33.39% -23.32% 9.87% - 2.15%
EBITDA Q/Q Growth		 -19.32% -32.10% 32.10% -22.50% 6.10% 18.29% -20.08% -0.67% 2.82% - -5.74%
EBIT Q/Q Growth		 -19.16% -31.59% 31.31% -21.10% 5.10% 16.40% -19.29% -0.49% 3.02% - -6.32%
NOPAT Q/Q Growth		 -13.70% -32.23% 28.96% -15.17% 2.59% 18.46% -18.48% -1.88% -1.12% - -4.21%
Net Income Q/Q Growth		 -19.64% -29.45% 30.29% -20.90% 5.08% 19.50% -22.74% -1.35% 3.82% - -6.60%
EPS Q/Q Growth		 -17.02% -30.91% 38.89% -4.55% 4.35% 29.55% -29.03% -2.50% 21.95% - -27.27%
Operating Cash Flow Q/Q Growth		 4.05% -12.00% -54.36% 32.81% 43.04% 162.69% -400.75% 15.24% 15.39% - -14.64%
Free Cash Flow Firm Q/Q Growth		 54.68% -26.16% 14.23% -27.78% 42.05% 176.15% 89.93% 10.52% -25.73% - 3.54%
Invested Capital Q/Q Growth		 -11.83% -60.17% 189.70% 2.05% -58.55% -366.82% -0.10% -9.53% -25.86% - -3.49%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
EBITDA Margin		 0.00% 0.00% -7,726.40% 0.00% -25,132.54% -1,966.01% -3,544.43% -4,653.00% -4,115.59% - -5,691.36%
Operating Margin		 0.00% 0.00% -8,179.53% 0.00% -25,948.33% -2,025.74% -3,603.30% -4,787.17% -4,405.96% - -5,917.52%
EBIT Margin		 0.00% 0.00% -7,834.69% 0.00% -25,461.72% -2,038.02% -3,650.07% -4,783.32% -4,222.29% - -5,857.83%
Profit (Net Income) Margin		 0.00% 0.00% -7,742.98% 0.00% -25,128.23% -1,936.60% -3,568.78% -4,716.68% -4,129.14% - -5,738.55%
Tax Burden Percent		 99.79% 100.00% 100.29% 99.76% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 99.20% 97.38% 98.54% 98.91% 98.69% 95.02% 97.77% 98.61% 97.79% - 97.96%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -98.86% 0.00% -681.94% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -93.61% 0.00% -673.40% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 81.34% 0.00% 598.56% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 -93.70% -88.19% -17.51% 0.00% -83.38% -136.88% -115.21% -154.81% -112.34% - -216.07%
Cash Return on Invested Capital (CROIC)		 0.00% -784.54% -428.86% -476.39% -674.56% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -14.74% 0.00% -71.23% -24.75% -43.90% -88.10% -70.32% - -75.87%
Return on Assets (ROA)		 0.00% 0.00% -14.57% 0.00% -70.30% -23.51% -42.92% -86.87% -68.77% - -74.33%
Return on Common Equity (ROCE)		 7.45% -88.19% -17.51% 0.00% -83.38% -136.88% -115.21% -154.81% -112.34% - -216.07%
Return on Equity Simple (ROE_SIMPLE)		 -88.56% 0.00% -83.89% 0.00% 0.00% 0.00% -188.93% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -36 -48 -34 -39 -38 -31 -37 -37 -38 -34 -35
NOPAT Margin		 0.00% 0.00% -5,725.67% 0.00% -18,163.83% -1,418.02% -2,522.31% -3,351.02% -3,084.17% - -4,142.27%
Net Nonoperating Expense Percent (NNEP)		 -9.71% -8.67% -5.25% -8.83% -8.54% -7.25% -8.57% -11.51% -6.58% - -9.77%
Return On Investment Capital (ROIC_SIMPLE)		 - -35.79% -13.88% -19.82% -20.03% -20.21% -34.30% -61.39% -23.35% -28.15% -46.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 1,887.99% 0.00% 6,746.89% 563.49% 913.62% 1,176.41% 914.94% - 2,033.29%
R&D to Revenue		 0.00% 0.00% 6,391.54% 0.00% 19,301.44% 1,562.25% 2,789.68% 3,710.76% 3,591.02% - 3,984.23%
Operating Expenses to Revenue		 0.00% 0.00% 8,279.53% 0.00% 26,048.33% 2,125.74% 3,703.30% 4,887.17% 4,505.96% - 6,017.52%
Earnings before Interest and Taxes (EBIT)		 -51 -67 -46 -56 -53 -44 -53 -53 -52 -47 -50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -67 -46 -56 -53 -43 -52 -52 -50 -46 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.79 6.48 3.44 3.14 2.45 2.50 2.44 5.33 4.61 - 8.19
Price to Tangible Book Value (P/TBV)		 4.79 6.48 3.44 3.14 2.45 2.50 2.44 5.33 4.61 - 8.19
Price to Revenue (P/Rev)		 0.00 0.00 1,420.60 1,043.92 580.65 128.39 67.87 65.37 124.73 - 155.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 26.64 64.93 19.03 13.47 20.68 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 1,064.05 768.34 361.24 64.55 30.36 44.86 89.05 - 122.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.82 -0.92 -0.87 -0.85 -0.89 -1.09 -1.01 -1.03 -1.11 - -1.52
Leverage Ratio		 1.24 1.23 1.20 1.24 1.49 1.72 1.82 2.09 2.04 - 3.39
Compound Leverage Factor		 1.23 1.20 1.18 1.22 1.47 1.63 1.78 2.06 2.00 - 3.32
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 9.85 4.35 5.29 2.65 -0.54 -1.42 -2.49 -3.32 -0.87 - -2.86
Noncontrolling Interest Sharing Ratio		 107.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.69 2.53 8.91 8.23 6.50 5.58 4.78 3.56 6.61 - 3.80
Quick Ratio		 4.20 2.16 8.62 7.85 6.09 5.02 4.21 2.99 6.09 - 3.73
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -37 -31 -40 -23 18 34 37 28 -15 -14
Operating Cash Flow to CapEx		 -1,346.37% -2,383.91% -2,913.38% -2,391.75% -2,029.13% 907.04% -2,017.22% -2,634.35% -14,185.83% - -19,957.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 - 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.00 0.00 0.03 0.03 0.04 0.13 0.16 0.21 0.26 - 0.18
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 29 11 33 34 14 -37 -37 -41 -51 -57 -59
Invested Capital Turnover		 0.00 0.00 0.02 0.02 0.04 -0.23 -1.79 -1.38 -0.32 - -0.08
Increase / (Decrease) in Invested Capital		 -6.94 -11 -2.37 1.24 -15 -49 -70 -75 -65 -20 -21
Enterprise Value (EV)		 763 741 629 454 289 193 117 223 532 - 493
Market Capitalization		 928 862 840 617 465 383 261 324 746 - 628
Book Value per Share		 $1.99 $1.37 $2.03 $1.64 $1.58 $1.17 $0.82 $0.46 $1.20 $0.67 $0.42
Tangible Book Value per Share		 $1.99 $1.37 $2.03 $1.64 $1.58 $1.17 $0.82 $0.46 $1.20 $0.67 $0.42
Total Capital		 194 133 244 197 190 153 107 61 162 121 77
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -165 -122 -211 -163 -176 -190 -144 -102 -213 -178 -135
Capital Expenditures (CapEx)		 2.91 1.84 2.32 1.90 1.28 1.79 2.42 1.57 0.25 0.29 0.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -35 -18 -13 33 -17 -15 -15 -17 -34 -34
Debt-free Net Working Capital (DFNWC)		 145 87 193 150 208 174 129 87 196 144 102
Net Working Capital (NWC)		 145 87 193 150 208 174 129 87 196 144 102
Net Nonoperating Expense (NNE)		 15 18 12 16 15 11 15 15 13 12 14
Net Nonoperating Obligations (NNO)		 -165 -122 -211 -163 -176 -190 -144 -102 -213 -178 -135
Total Depreciation and Amortization (D&A)		 0.32 0.16 0.64 0.13 0.69 1.57 1.54 1.45 1.31 1.09 1.43
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -2,962.78% -2,168.19% 4,083.38% -553.70% -384.27% -293.73% -282.75% - -840.28%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 32,692.56% 25,389.85% 26,024.25% 5,830.54% 3,366.54% 1,757.27% 3,285.71% - 2,518.59%
Net Working Capital to Revenue		 0.00% 0.00% 32,692.56% 25,389.85% 26,024.25% 5,830.54% 3,366.54% 1,757.27% 3,285.71% - 2,518.59%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22) ($0.28)
Adjusted Weighted Average Basic Shares Outstanding		 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M 177.10M
Adjusted Diluted Earnings per Share		 ($0.55) ($0.72) ($0.44) ($0.46) ($0.44) ($0.31) ($0.40) ($0.41) ($0.32) ($0.22) ($0.28)
Adjusted Weighted Average Diluted Shares Outstanding		 91.85M 90.97M 104.47M 119.19M 119.76M 118.60M 130.88M 129.19M 160.50M 148.76M 177.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 97.32M 119.94M 120.03M 120.03M 131.16M 131.16M 131.29M 134.57M 180.51M 180.55M 180.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -36 -48 -34 -39 -38 -31 -37 -37 -38 -34 -35
Normalized NOPAT Margin		 0.00% 0.00% -5,725.67% 0.00% -18,163.83% -1,418.02% -2,522.31% -3,351.02% -3,084.17% - -4,142.27%
Pre Tax Income Margin		 0.00% 0.00% -7,720.30% 0.00% -25,128.23% -1,936.60% -3,568.78% -4,716.68% -4,129.14% - -5,738.55%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%

Financials Breakdown Chart

Key Financial Trends

Prime Medicine (PRME) exhibits the cash burn and funding dynamics typical of an early-stage biotech, with small quarterly revenue, heavy R&D spend, and ongoing net losses. Below is a concise, data-driven snapshot of the last four years of quarterly results, focusing on trends most relevant to retail investors.

  • Significant equity financing in Q3 2025: Prime Medicine added about $144.8 million in net cash from financing activities, reflecting a substantial capital raise to bolster liquidity.
  • Growing asset base through 2025: Total assets rose from roughly $311.4 million (Q4 2024) to about $385.0 million (Q3 2025), indicating expansion of the company's asset base.
  • Investment cash inflow in Q3 2025: Sale/maturity of investments contributed about $42.4 million in cash, supporting liquidity in that quarter.
  • Positive investing cash flow in Q4 2025: Net cash from continuing investing activities was about $28.3 million, signaling favorable investing activity that quarter.
  • Reasonable near-term liquidity in early 2025: Cash & equivalents on the balance sheet reached about $91.9 million in Q1 2025, indicating a solid cash cushion before subsequent funding rounds.
  • Revenue remains very small and fluctuates modestly around $1.1–$1.5 million per quarter (Q1 2025: $1.45M; Q2 2025: $1.12M; Q3 2025: $1.23M; Q4 2025: $0.84M).
  • R&D and SG&A drive most costs: R&D expenses run high (e.g., Q4 2025: $34.71M; Q3 2025: $43.99M) alongside substantial SG&A (e.g., Q4 2025: $14.74M), underscoring heavy upfront spend typical of pipeline development.
  • Earnings per share and shares outstanding: Negative earnings per share persist (Q4 2025 Basic EPS around -$0.22; Q3 2025 around -$0.32; Q2 2025 around -$0.41), with weighted average shares outstanding hovering around 130–181 million across 2025.
  • Ongoing quarterly losses: Net income/(loss) for 2025 consistently remained deeply negative (Q4 2025 about -$46.1M; Q3 2025 about -$50.6M; Q2 2025 about -$52.6M; Q1 2025 about -$51.9M), illustrating the high cost of early-stage development without product commercial revenue yet.
  • Negative operating cash flow in 2025: Prime Medicine reported substantial cash burn from operations (example: Q4 2025 net cash from continuing operating activities about -$37.3M; Q3 2025 about -$35.0M; Q2 2025 about -$41.4M; Q1 2025 about -$48.9M), indicating ongoing liquidity risk unless funded by external financing.
07/05/26 08:58 AM ETAI Generated. May Contain Errors.

Prime Medicine Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prime Medicine's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Prime Medicine's net income appears to be on an upward trend, with a most recent value of -$201.14 million in 2025, rising from -$3.41 million in 2020. The previous period was -$195.88 million in 2024. Find out what analysts predict for Prime Medicine in the coming months.

Prime Medicine's total operating income in 2025 was -$208.35 million, based on the following breakdown:
  • Total Gross Profit: $4.63 million
  • Total Operating Expenses: $212.98 million

Over the last 5 years, Prime Medicine's total revenue changed from $5.21 million in 2020 to $4.63 million in 2025, a change of -11.1%.

Prime Medicine's total liabilities were at $221.87 million at the end of 2025, a 53.7% increase from 2024, and a 256.1% increase since 2021.

In the past 4 years, Prime Medicine's cash and equivalents has ranged from $41.57 million in 2023 to $187.62 million in 2022, and is currently $63.03 million as of their latest financial filing in 2025.

Over the last 5 years, Prime Medicine's book value per share changed from 0.00 in 2020 to 0.67 in 2025, a change of 67.0%.


Related Companies

Financial statements for NASDAQ:PRME last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel